Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg ...

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

Zepbound is also prescribed to treat moderate to severe obstructive sleep apnea in adults with obesity ... such as your treatment plan and the pharmacy you use. Here are a few things to consider ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

said the new Zepbound discount may not be enough for many of the people who are most at risk of obesity. “It is a good step in expanding access to effective obesity treatment options to more ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

If you or a loved one has sleep apnea, you may be considering different treatment options. A new treatment you may hear about is Zepbound (tirzepatide). In December 2024, Zepbound became the ...